The Democratic Republic of the Congo started using an experimental vaccine against the deadly Ebola virus yesterday after identifying it as the virulent Zaire strain. The latest outbreak has spread to a conflict region and is suspected of killing at least 36 people during its first week.
Why it matters: Testing and approving an Ebola vaccine is a priority for global health officials as further outbreaks are expected — and the U.S. hopes to get the Food and Drug Administration to consider approval for a vaccine in 18 months or so.
"As I said before in May [during prior DRC Ebola outbreak], 'It's not over yet, folks, because this is going to come back.'"— Anthony Fauci, director, National Institute of Allergy and Infectious Diseases